Novel therapies for osteoporosis

Bibliography

• Bibliography Papers of special note have been highlighted as either of interest (*) or of considerable interest (88) to readers.
   Google Scholar
• JEPPESEN PB, HARTMANN B, THULESEN J et al.: Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology (2001) 120:806–815.
   PubMed Web of Science ®Google Scholar
• HADERSLEV KV, JEPPESEN PB, HARTMANN B et al: Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand. Gastroenterol (2002) 37:392–398.
   Google Scholar
• ALBRIGHT F, AUB JC, BAUER W: Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proven cases from one clinic. JAMA (1934) 102:1276–1287.
   Google Scholar
• RUBIN MR, COSMAN F, LINDSAY R, BILEZIKIAN JP: The anabolic effects of parathyroid hormone. Osteop. Internat. (2002) 13:267–277.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the effects of PTH on bone.
   Google Scholar
• BAUER W, AUB JC, ALBRIGHT F: Studies of calcium and phosphorous metabolism. V. A study of the bone trabeculae as a readily reversible supplementary of calcium. I Exp. Med. (1929) 49:145–161.
   Google Scholar
• TAM CS, HEERSCHE JN, MURRAY TM, PARSONS JA: Parathyhroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continous administration. Endocrinology (1982) 110:506–512.
   PubMed Web of Science ®Google Scholar
• NEER RIVI, ARNAUD CD, ZANCHETTE JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl. J. Med. (2001) 344:1434–1441.
   PubMed Web of Science ®Google Scholar
• •A large, prospective study of PTH (1–34) treatment showing decreased fracture, resulting in approval by the FDA for osteoporosis treatment.
   Google Scholar
• RITTMASTER RS, BOLOGNESE M, ETTINGER MP et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. I Clin. Endocrin. Metab. (2000) 85:2129–2134.
   PubMed Web of Science ®Google Scholar
• CANALIS E, HOTT M, DELOFFRE P, TSOUDEROS Y, MARIE PJ: The divalen strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone (1996) 18:517–523.
   PubMed Web of Science ®Google Scholar
• MARIE PJ, HOTT M, MODROWSKI D et al.: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res. (1993) 8:607–615.
   PubMed Web of Science ®Google Scholar
• BOIVIN G, DELOFFRE P, PERRAT B et al.: Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (5 12911) administration. I Bone Miner. Res. (1996) 11:1302–1311.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, SLOSMAN DO, DELMAS PD et al: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. Clin. Endocrinol Metab. (2002) 87:2060–2066.
   Google Scholar
• •A large, multi-centre study showing improved BMD with strontium treatment for osteoporosis.
   Google Scholar
• REGINSTER JY, DEROISY R, DOUGADOS M et al.: Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos. mt. (2002) 13:925–931.
   PubMed Web of Science ®Google Scholar
• HENDRIX SL, MCNEELEY SG: Effect ofselective estrogen receptor modulators on reproductive tissues other than endometrium. Ann. NY Acad. Sci. (2001) 949:243–250.
   PubMed Web of Science ®Google Scholar
• SATO M, TURNER CH, WANG T et al:LY353381.HC1: a novel raloxifene analog with improved SERM potency and efficacy in vivo. I Pharm. Exp. Ther. (1998) 287:1–7.
   Google Scholar
• SATO M, ZENG GQ, ROWLEY E, TURNER CH: LY353381-HC1: an improved benzothiophene analog with bone efficacy comlementary to parathyroid hormone (1-34). Endocrinology (1998) 139:4642–4651.
   PubMed Web of Science ®Google Scholar
• SUH N, GLASEBROOK AL, PALKOWITZ AD et al: Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. (2001) 61:8412–8415.
   PubMed Web of Science ®Google Scholar
• RONKIN S, CLARKE L, BOUDES P, CONSTANTINE B: TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. J. Bone Miner. Res. (2001) 16:S413.
   Web of Science ®Google Scholar
• •An abstract showing dose-dependent suppression of markers of bone turnover with bazedoxifene.
   Google Scholar
• YLIKORKALA NO: Data presented at 2002 North American Menopause Society. Meeting of North American Menopause Society Chicago, IL, USA (2002).
   Google Scholar
• KE HZ, PARALKAR VM, GRASSER WA et al: Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology (1998) 139:2068–2076.
   PubMed Web of Science ®Google Scholar
• MOFFETT A: Emerging data and experience with lasofoxifene: highlights from clinical trials. Symposium at International Osteoporosis Foundation - World Congress on Osteoporosis, Lisbon, Portugal (2002).
   Google Scholar
• CHAVASSIEUX P, GARNERO P, DUBOEUF F et al.: Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study. J. Bone Miner. Res. (2001) 16:89–96.
   PubMed Web of Science ®Google Scholar
• AMMANN P, BOURRIN S, BONJOUR JP, MEYER JM, RIZZOLI R: The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats. Osteoporos. hat. (1999) 10:376.
   Google Scholar
• BOURRIN S, AMMANN P, BONJOUR JP, RIZZOLI R: Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone (2002) 30:195–200.
   PubMed Web of Science ®Google Scholar
• ALEXANDERSEN P, RIIS BJ, STAKKESTAD JA, DELMAS PD, CHRISTIANSEN C: Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. Clin. Endocrin. Metab. (2001) 86:755–760.
   Google Scholar
• MODELSKA K, CUMMINGS S: Tibolone for postmenopausal women: systematic review of randomized trials. .1. Clin. Endocrin. Metab. (2002) 87:16–23.
   PubMed Web of Science ®Google Scholar
• GALLAGHER JC, BAYLINK DJ, FREEMAN R, MCCLUNG MR: Prevention of bone loss with tibolone in postmenopausal women: results of two randomized double-blind, placebo-controlled, dose-finding studies. I Clin. Endocrin. Metab. (2001) 86:4717–4726.
   PubMed Web of Science ®Google Scholar
• •Results of two large randomised studies showing that tibolone increases bone density in postmenopausal women.
   Google Scholar
• RYMER J, ROBINSON J, FOGELMAN I: Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos. mt. (2001) 12:478–483.
   PubMed Web of Science ®Google Scholar
• STUDD J, ARNALA I, KICOVIC PM et al.: A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet. Cynecol (1998) 92:574–579.
   Web of Science ®Google Scholar
• MILNER M, HARRISON RF, GILLIGAN E, KELLY A: Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause (2000) 7:327–333.
   PubMed Web of Science ®Google Scholar
• HAMMAR M, CHRISAU S, NATHORST-BOOS J, RUD T, GARRE K: A double-blind, randomised trial comparing the effects of tibolone and continous combined hormone replacemnt therapy in postmenopausal women with menopausal symptoms. Br. J. Obstet. Cynaec. (1998) 105:904–911.
   PubMedGoogle Scholar
• BERNING B, VAN KUIJK C, COELINGH BENNINK HJT, FAUSER BCJM: Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas (2000) 35:81–88.
   PubMed Web of Science ®Google Scholar
• GARNERO P, JAMIN C, BENHAMOU CL, PELISSIER C, ROUX C: Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. Hum. Reprod. (2002) 17:2748–2753.
   PubMed Web of Science ®Google Scholar
• BARNES S, PETERSON TG: Biochemicaltargets of the isoflavone genistein in tumor cell lines. Proc. Soc. Exp. Biol. Med. (1995) 208:103–108.
   PubMed Web of Science ®Google Scholar
• MAZUR W, ADLERCREUTZ H: Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition (2000) 16:654–658.
   PubMed Web of Science ®Google Scholar
• SOMEKAWA Y, CHIGUCHI M, ISHIBASHI T, ASO T: Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet. Cynecol (2001) 97:109–115.
   Web of Science ®Google Scholar
• MET J, YEUNG SSC, KUNG AWC: Highdietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premeonapusal women. I Clin. Endocrin. Metab. (2001) 86:5217–5221.
   PubMed Web of Science ®Google Scholar
• ADAMI S, BUFALINO L, CERVETTI R et al.: Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteop. Internat. (1997) 7:119–125.
   PubMed Web of Science ®Google Scholar
• GENNARI C, AGNUSDEI D, CREPALDI G et al.: Effect of ipriflavone - a synthetic derivative of natural isoflavones-on bone mass loss in the early years after menopause. Menopause (1998) 5:9–15.
   PubMed Web of Science ®Google Scholar
• CLIFTON-BLIGH PB, BABER RJ, FULCHER GR, NERY ML, MORETON T: The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause (2001) 8:259–265.
   PubMed Web of Science ®Google Scholar
• ALEXANDERSEN P, TOUSSAINT A, CHRISTIANSEN C et al.: Ipriflavone in the treatment of postmenopausal osteoporosis. JAMA (2001) 285:1482–1488.
   PubMed Web of Science ®Google Scholar
• •A large, multi-centre European study which showed no benefit of ipriflavone on bone density or fractures. Ipriflavone subjects developed neutropenia.
   Google Scholar
• DUNFORD JE, THOMPSON K, COXON FP et al: Strucuture-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. j Pharm. Exp. Ther. (2001) 296:235–242.
   PubMed Web of Science ®Google Scholar
• SZABO CM, MARTIN MB, OLDFIELD E: An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. J. Med. Chem. (2002) 45:2894–2903.
   PubMed Web of Science ®Google Scholar
• RAVN P, CLEMMESEN B, RIIS BJ, CHRISTIANSEN C: The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopuasal osteopororosis: a 1-year, randomized, double-bline, placebo-controlled dose-finding study. Bone (1996) 19:527–533.
   PubMed Web of Science ®Google Scholar
• RIIS BJ, ISE J, VON STEIN T, BAGGER Y, CHRISTIANSEN C: Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. Bone Miner. Res. (2001) 16:1871–1878.
   PubMed Web of Science ®Google Scholar
• •A study comparing daily versus intermittent dosing of ibandronate. Intermittent dosing regimens showed loss of bone suppression between doses.
   Google Scholar
• MORII H, NISHIZAWA Y, TAKETANI Y et al.: A randomized controlled trial with ONO-5920 (minodronate/YM529) in Japanese patients with postmenopausal osteoporosis. Bone Miner. Res. (2002) 17:M342.
   Google Scholar
• REID IR, BROWN JP, BURCKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl. J. Med. (2002) 346:653–661.
   PubMed Web of Science ®Google Scholar
• •A study showing equivalent efficacy with every 3, 6 or 12 month dosing with sustained suppression of bone resorption.
   Google Scholar
• PECHERSTORFER M, LOHO N, MIRZAI S et al: Tr-monthly intravenous injections of ibandronate (2 mg) for treatment of postmenopausal osteoporosis. J. Bone Miner. Res. (2001) 16S1:5406.
   Google Scholar
• FAHRLEITNER A, PRENNER G, LEB Get al.: Combination therapy with ibandronate and calcitriol is effective in patients following liver transplantation. Bone Miner. Res. (2001) 16S1:5287.
   Google Scholar
• SIMONET WS, LACEY DL, DUNSTAN CR et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 89:309–319.
   PubMed Web of Science ®Google Scholar
• TSUDA E, GOTO M, MOCHIZUKI Y et al.: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. (1997) 234:137–142.
   PubMed Web of Science ®Google Scholar
• LACEY DL, TIMMS E, TAN HL et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 93:165–176.
   PubMed Web of Science ®Google Scholar
• YASUDA H, SHIMA N, NAKAGAWA N et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA (1998) 95:3597–3602.
   PubMed Web of Science ®Google Scholar
• •Phase I study of OPG showing prolonged suppression of markers of bone turnover after one subcutaneous dose.
   Google Scholar
• BUCAY N, SAROSI I, DUNSTAN CR et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. (1998) 12:1260–1268.
   PubMed Web of Science ®Google Scholar
• BEKKER PJ, HOLLOWAY D, NAKANISHI A et al.: The effect of a single dose of osteoprotegerin in postmenopausal women. I Bone Miner. Res. (2001) 16:348–360.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP GB, JAMES IE et al.: A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone (2002) 30:746–753.
   PubMed Web of Science ®Google Scholar
• STROUP GB, LARK MW, VEBER DF et al.: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. j Bone Miner. Res. (2001) 16:1739–1746.
   PubMed Web of Science ®Google Scholar
• •Animal study showing efficacy in preventing bone loss in hypogonadal primates.
   Google Scholar
• HARTMAN GD, DUGGAN ME: avI33 Integrin antagonists as inhibitors of bone resorption. Expert Opin. Invest. Drugs (2000) 9:1281–1291.
   PubMed Web of Science ®Google Scholar
• MOUSA SA: Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Carr. Opin. Chem. Biol. (2002) 6:534–541.
   PubMed Web of Science ®Google Scholar
• MILLER WH, BONDINELL WE, COUSINS RD et al.: Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg. Med. Chem. Lett. (1999) 9:1807–1812.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP GB, HWANG SM et al.: Design and characterization of orally active Arg-Gly-Asp epetidomimetic vitronectin receptor antagonist SB 265123 for prevedtion of bone loss in osteoporosis. Pharm. Exp. Therap. (1999) 291:612–617.
   PubMed Web of Science ®Google Scholar
• •A study showing inhibition of bone loss in an animal model of osteoporosis treated with SB265123, an integrin receptor antagonist.
   Google Scholar
• HUGHES FJ, BUTTERY LDK, HUKKANEN MVJ et al.: Cytokine-induced prostaglandin E2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and - independent mechanism in rat osteoblasts M vitro. I Biol. Chem. (1999) 274:1776–1782.
   Web of Science ®Google Scholar
• VAN 'T HOF RJ, ARMOUR KJ, SMITH LM et al: Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc. Nati Acad. ScL USA (2000) 97:7993–7998.
   PubMed Web of Science ®Google Scholar
• AKATSU T, TAKAHASHI N, UDAGAWA N et al: Role of prostaglandins in interleukin-1 -induced bone resorption in mice M vitro. Bone Miner. Res. (1991) 6:183–190.
   PubMed Web of Science ®Google Scholar
• MORTON DJ, BARRETT CE, SCHNEIDER DL: Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. Bone Miner. Res (1998) 13:1924–1931.
   PubMed Web of Science ®Google Scholar
• MACINTYRE I, ZAIDI M, TOWHIDUL ALAM ASM et al.: Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc. Natl Acad. Sci. USA (1991) 88:2936–2940.
   PubMed Web of Science ®Google Scholar
• WIMALAWANSA S, CHAPA T, FANG L et al.: Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. Bone Miner. Res. (2000) 15:1119–1125.
   PubMed Web of Science ®Google Scholar
• ARMOUR KJ, VAN 'T HOF RJ, ARMOUR KE et al.: Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprogen nitroxybutylester (HCT-1026). Arthritis Rheum. (2001) 44:2185-2192. Study showing prevention of bone loss in OVX mice treated with HCT-1026, a NO-NSAID.
   Google Scholar
• SHAKESPEARE W, YANG M, BOHACEK R et al.: Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA (2000) 97:9373–9378.
   PubMed Web of Science ®Google Scholar
• MISSBACH M, JESCHKE M, FEYE J et al.: A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of tis major cellular substrates and reduces bone resorption M vitro and in rodent models M vivo. Bone (1999) 24:437–449.
   PubMed Web of Science ®Google Scholar
• •Study showing in vitro and in vivo effects of a Src inhibitor on bone resorption.
   Google Scholar
• MUNDY GR, GARRETT R, HARRIS S et al.: Stimulation of bone formation M vitro and in rodents by statins. Science (1999) 286:1946–1949.
   PubMed Web of Science ®Google Scholar
• CHUNG YS, LEE MD, LEE SK, KIM HM, FITZPATRICK LA: HMG-CoA Reductase inhibitors increase BMD in Type 2 diabetes mellitus patients. Clio. Endocrin. Metab. (2000) 85:1137–1142.
   PubMed Web of Science ®Google Scholar
• EDWARDS CJ, HART DJ, SPECTOR TD: Oral statins and increased bone mineral density in postmenopausal women. Lancet (2000) 355:2218–2219.
   PubMed Web of Science ®Google Scholar
• SIROLA J, HONKANEN R, KROEGER H et al.: Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos. mt. (2002) 13:537–541.
   PubMed Web of Science ®Google Scholar
• CAULEY JA, JACKSON R, PETTINGER M et al.: Statin use and bone mineral density (BMD) in older women: the women's health initiative observational study (VVHI-OS). j Bone Miner. Res. (2000) 15S1:S155.
   Google Scholar
• CHAN KA, ANDRADE SE, BOLES M et al.: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet (2000) 355:2185–2188.
   PubMed Web of Science ®Google Scholar
• WANG PS, SOLOMON DH, MOGUN H, AVORN J: HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA (2000) 283:3211–3216.
   PubMed Web of Science ®Google Scholar
• MEIER CR, SCHLIENGER RG, KRAENZLIN ME, SCHLE GEL B, JICK H: HMG-CoA reductase inhibitors and the risk of fractures. JAMA (2000) 283:3205–3210.
   PubMed Web of Science ®Google Scholar
• •Case control study using the General Practice Research Database from the UK showing decreased fracture risk with statin use.
   Google Scholar
• VAN STAA TP, WEGMAN S, DE VRIES F, LEUFKENS B, COOPER C: Use of statins and risk of fractures. JAM (2001) 285:1850–1855.
   PubMed Web of Science ®Google Scholar
• •Case control study using the General Practice Research Database from the UK showing no evidence for decreased fracture risk with statin use.
   Google Scholar
• REID IR, HAGUE W, EMBERS ON J et al.: Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet (2001) 357:509–512.
   Google Scholar
• LACROIX AZ, CAULEY JA, JACKSON R et al.: Does statin use reduce risk of fracture in postmenopausal women? Bone Miner. Res. (2000) 15S1:S155.
   Google Scholar
• BAUER DC, BLACK DM, VAN DER KLIFT M: Statin use and fracture: a meta-analysis of 8 observational studies. Bone (2001) 28S:S89.
   Google Scholar
• MUNDY GR: Statins and their potential for osteoporosis. Bone (2001) 29:495–497.
   PubMed Web of Science ®Google Scholar
• •A brief review of the effects of statins in vitro, in animal studies and in clinical trials.
   Google Scholar